Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795360 | PMC |
| http://dx.doi.org/10.3389/fmedt.2021.841150 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Scale-up and clinical bioavailability assessment of a 45% drug loaded amorphous nanoparticle formulation of a BCS IV compound for oral delivery.
J Pharm Sci
January 2025
Small molecule CMC development, Drug Product Development, AbbVie Inc., North Chicago, IL 60064, United States. Electronic address:
A 45 % drug loaded (DL) amorphous nanoparticle (ANP) formulation for a BCS IV drug demonstrated promising pharmacokinetics in dogs (Purohit, et al., J. Pharm.
View Article and Find Full Text PDFMolecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit from tumor suppressor expression.
Front Neurosci
September 2023
Department of Molecular Carcinogenesis, Medical University of Lodz, Lodz, Poland.
Introduction: Glioblastoma (GBM) is notorious for its clinical and molecular heterogeneity, contributing to therapeutic failure and a grim prognosis. is one of the tumor suppressor genes important in nervous tissue or related pathologies, which was scarcely investigated in GBM for reliable associations with prognosis or disease progression despite known alterations. Recently, we observed a phenotypic heterogeneity between GBM cell lines (U87MG, T98G, U251MG, DBTRG-05MG), among which the anti-GBM activity of was generally corresponding, but colony growth and formation were inconsistent in DBTRG-05MG.
View Article and Find Full Text PDFListening to the Patient Voice Adds Value to Cancer Clinical Trials.
J Natl Cancer Inst
October 2022
Johns Hopkins Bloomberg School of Public Health and School of Medicine, Baltimore, MD, USA.
Randomized clinical trials are critical for evaluating the safety and efficacy of interventions in oncology and informing regulatory decisions, practice guidelines, and health policy. Patient-reported outcomes (PROs) are increasingly used in randomized trials to reflect the impact of receiving cancer therapies from the patient perspective and can inform evaluations of interventions by providing evidence that cannot be obtained or deduced from clinicians' reports or from other biomedical measures. This commentary focuses on how PROs add value to clinical trials by representing the patient voice.
View Article and Find Full Text PDFEditorial: Data-Enabled Intelligence for Medical Technology Innovation, Volume I.
Front Med Technol
January 2022
Department of Computing and Mathematics, Manchester Metropolitan University, Manchester, United Kingdom.
Guest Editorial: Special Topic on Data-Enabled Theoretical Chemistry.
J Chem Phys
June 2018
Departments of Chemistry and Physics, University of California, Irvine, California 92697, USA.
A survey of the contributions to the Special Topic on Data-enabled Theoretical Chemistry is given, including a glossary of relevant machine learning terms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!